Squarepoint
TVTX icon

Squarepoint’s Travere Therapeutics TVTX Stock Holding History

Squarepoint’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$636K Buy
+11,200
New +$497K ﹤0.01% 3233
2025
Q2 		– Sell
-24,300
Closed -$435K – 5070
2025
Q1 		$435K Buy
+24,300
New +$493K ﹤0.01% 3432

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's TVTX Position: Q2 2026 in Review

Squarepoint reduced its Travere Therapeutics (TVTX) stake by 45% in Q2 2026, selling an estimated $4M and leaving 109,807 shares worth $6.24M. The position accounts for 0.01% of the portfolio, ranked #1412.

Squarepoint first reported a position in TVTX in Q4 2015 and has held it in 33 quarters since. The position peaked at $12.2M in Q4 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Squarepoint held 109,807 shares of Travere Therapeutics worth $6.24M as of Q2 2026.
  • Squarepoint sold 90,304 Travere Therapeutics shares in Q2 2026, an estimated $4M.
  • Travere Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1412 holding.
  • Squarepoint first reported a position in Travere Therapeutics in Q4 2015 and has held it in 33 quarters since.
  • Squarepoint's Travere Therapeutics position peaked at $12.2M in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.